Lyell Immunopharma, Inc.

lyell.com

What Do They Do?

Develops cancer treatments made from patients’ immune cells for people with blood cancers and solid tumors.

How Do They Make Money?

FY2025 revenue

Do Revenues Turn Into Profits?

No. It lost $274.4M in FY2025.

Operating income, FY2025

−748344% of revenue

▼ −25% (Loss) vs FY2024 (−$358.8M, −588123%)

Net income, FY2025

−762356% of revenue

▼ −20% (Loss) vs FY2024 (−$343M, −562285%)

Free cash flow, FY2025

−418900% of revenue

▼ −7% (Loss) vs FY2024 (−$162.9M, −266980%)

How Are They Changing?

Since the FY2025 annual report

Latest quarter: Q2 FY2026, the three months to Jun 30, 2026

Revenue: ▼ −50%; vs $8K in Q2 FY2025
Net income: ▲ +5% (Loss); vs −$42.7M in Q2 FY2025

Shrinking. Revenue fell 100% in 4 years, from $10.7M in FY2021 to $36K in FY2025, about 76% a year.

Focus and treatment approach The older report described a pipeline focused on solid tumors and included CAR, TIL and TCR therapies. The latest report describes candidates for blood cancers as well as solid tumors and centers its pipeline on CAR T-cell therapies.

Who Do They Compete With?

Competes with Agenus, Akeso, Arcellx, Allogene Therapeutics, Arsenal Biosciences, AstraZeneca, Autolus Therapeutics, Bristol Myers Squibb, Caribou Biosciences, Gilead Sciences, Immunocore Holdings, Johnson & Johnson, Nanjing Legend Biotech, Novartis, Pfizer, Poseida/F. Hoffmann-La Roche, Summit Therapeutics, Amgen, AbbVie, and CytomX

Comments